Mr. Arun Menawat reports

TELIX ANNOUNCES COLLABORATIONS TO EXPLORE PSMA-PET IMAGING IN EMERGING PROSTATE CANCER TREATMENT APPROACHES

Telix Pharmaceuticals Ltd. has entered into letters of intent to pursue collaborations with EDAP TMS S.A. and Profound Medical Corp. These initiatives reflect Telix's commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.

• Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer;
• Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice;
• Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes.

The collaborations will explore the investigational use of Telix's PSMA-PET1 imaging agents Gozellix (kit for the preparation of gallium Ga 68 gozetotide) and Illuccix (kit for the preparation of gallium Ga 68 gozetotide) with robotic high-intensity focused ultrasound (HIFU), and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation (TULSA).

Telix's intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational and research engagement.

"We are uniquely designed to enable the integration of PSMA-PET imaging with Focal One's real-time ultrasound and fully robotic energy delivery to optimize treatment efficacy while minimizing side effects," said Ryan Rhodes, EDAP chief executive officer. "As the market leader in robotic focal therapy, with a growing global installed base, this collaboration will accelerate the development and standardization of treatment strategies to further personalize focal therapy treatments using Telix's PSMA-PET imaging agents and Focal One Robotic HIFU."

"Emerging clinical evidence suggests PSMA imaging may support prostate whole-gland, partial-gland and focal ablation workflows, from treatment planning through post-treatment monitoring," said Arun Menawat, Profound's chief executive officer and chairman. "In collaboration with Telix, we look forward to exploring optimized workflows and generating clinical evidence that may help establish best practices and accelerate adoption of PSMA-PET imaging and the MRI-guided Tulsa procedure."

"Precision medicine requires precision treatment strategies," said Kevin Richardson, chief executive officer, Telix Precision Medicine. "As disruptive technologies continue to transform prostate cancer care, we believe PSMA-PET imaging has the potential to play an important role in helping inform clinical decision making across a range of minimally invasive and image-guided treatment approaches. We are excited to explore collaborations with market leaders in EDAP and Profound that may further advance personalized care for patients."

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One in Europe and the United States as a leading prostate focal therapy platform controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures. The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate ablation. Physicians use the Tulsa procedure to see, ablate and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care -- from whole gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared by the Food and Drug Administration in the United States for transurethral ultrasound ablation (Tulsa) of prostate tissue. In addition, Tulsa-Pro is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE (United Arab Emirates).

About Telix Pharmaceuticals Ltd.

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

We seek Safe Harbor.